Should I buy or sell Vaxart stock right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 1 hold rating and 3...
What is Vaxart's stock price forecast for 2022?
4 Wall Street research analysts have issued twelve-month target prices for Vaxart's stock. Their VXRT stock forecasts range from $6.00 to $18.00. O...
How has Vaxart's stock performed in 2022?
Vaxart's stock was trading at $6.27 on January 1st, 2022. Since then, VXRT shares have decreased by 48.8% and is now trading at $3.21. View the be...
When is Vaxart's next earnings date?
Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Vaxart .
How were Vaxart's earnings last quarter?
Vaxart, Inc. (NASDAQ:VXRT) posted its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($0.20) earnings per share...
When did Vaxart's stock split? How did Vaxart's stock split work?
Vaxart's stock reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of s...
Who are Vaxart's key executives?
Vaxart's management team includes the following people: Mr. Cezar Andrei Floroiu M.B.A. , CEO, Pres, Principal Financial Officer & Director (Age...
Who are some of Vaxart's key competitors?
Some companies that are related to Vaxart include Relay Therapeutics (RLAY) , Twist Bioscience (TWST) , Krystal Biotech (KRYS) , Allogene Thera...
What other stocks do shareholders of Vaxart own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO)...
About Vaxart
Vaxart (NASDAQ:VXRT) Frequently Asked Questions
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Signals & Forecast
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vaxart stock. View analyst ratings for Vaxart or view top-rated stocks.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Vaxart stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock.
Is Vaxart stock A Buy?
Vaxart finds support from accumulated volume at $4.30 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are negative selling more shares than they are buying in Vaxart
Vaxart holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 26.13 million shares bought and 53.77 million shares sold. The last trade was done 10 days ago by Berg Edward B who bough 285 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
